Drug Trial Radar · NCT03866382
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
314
Planned (sponsor's estimate)
Start
May 13, 2019
Primary completion
Feb 28, 2027
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Conditions
- Bladder Adenocarcinoma
- Bladder Clear Cell Adenocarcinoma
- Bladder Mixed Adenocarcinoma
- Bladder Neuroendocrine Carcinoma
- Bladder Small Cell Neuroendocrine Carcinoma
- Bladder Squamous Cell Carcinoma
- Chromophobe Renal Cell Carcinoma
- Collecting Duct Carcinoma
- Invasive Bladder Giant Cell Urothelial Carcinoma
- Invasive Bladder Lymphoepithelioma-Like Carcinoma
- Invasive Bladder Nested Urothelial Carcinoma
- Invasive Bladder Plasmacytoid Urothelial Carcinoma
- Invasive Bladder Sarcomatoid Urothelial Carcinoma
- Invasive Bladder Urothelial Carcinoma
- Kidney Medullary Carcinoma
- Large Cell Neuroendocrine Carcinoma
- Malignant Testicular Leydig Cell Tumor
- Malignant Testicular Sertoli Cell Tumor
- Metastatic Bladder Carcinoma
- Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma
- Metastatic Bladder Giant Cell Urothelial Carcinoma
- Metastatic Bladder Large Cell Neuroendocrine Carcinoma
- Metastatic Bladder Lipid-Rich Urothelial Carcinoma
- Metastatic Bladder Micropapillary Urothelial Carcinoma
- Metastatic Bladder Plasmacytoid Urothelial Carcinoma
- Metastatic Bladder Sarcomatoid Urothelial Carcinoma
- Metastatic Bladder Small Cell Neuroendocrine Carcinoma
- Metastatic Bladder Squamous Cell Carcinoma
- Metastatic Chromophobe Renal Cell Carcinoma
- Metastatic Kidney Medullary Carcinoma
- Metastatic Malignant Genitourinary System Neoplasm
- Metastatic Papillary Renal Cell Carcinoma
- Metastatic Penile Carcinoma
- Metastatic Prostate Small Cell Neuroendocrine Carcinoma
- Metastatic Sarcomatoid Renal Cell Carcinoma
- Metastatic Urethral Carcinoma
- Papillary Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage IV Bladder Cancer AJCC v8
- Stage IV Penile Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Urethral Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8
- Urachal Adenocarcinoma
- Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen CollectionProcedure
Undergo blood and urine sample collection
Bone ScanProcedure
Undergo bone scan
Cabozantinib S-malateDrug
Given PO
Computed TomographyProcedure
Undergo CT and/or PET/CT scan
Echocardiography TestProcedure
Undergo echocardiography
IpilimumabBiological
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to 5 years
Locations
582 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Suspended
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Suspended
Alaska Women's Cancer Care
Anchorage, Alaska · Suspended
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Suspended
Providence Alaska Medical Center
Anchorage, Alaska · Suspended
Kingman Regional Medical Center
Kingman, Arizona · Suspended
Cancer Center at Saint Joseph's
Phoenix, Arizona · Active not recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
University of Arizona Cancer Center-Orange Grove Campus
Tucson, Arizona · Active not recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Active not recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Active not recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas · Suspended
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Active not recruiting
PCR Oncology
Arroyo Grande, California · Suspended
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Suspended
Community Cancer Institute
Clovis, California · Active not recruiting
University Oncology Associates
Clovis, California · Active not recruiting
Epic Care-Dublin
Dublin, California · Active not recruiting
Bay Area Breast Surgeons Inc
Emeryville, California · Active not recruiting
Epic Care Partners in Cancer Care
Emeryville, California · Active not recruiting
Marin Cancer Care Inc
Greenbrae, California · Suspended
Keck Medicine of USC Koreatown
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California · Completed
Contra Costa Regional Medical Center
Martinez, California · Active not recruiting
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California · Recruiting
Alta Bates Summit Medical Center - Summit Campus
Oakland, California · Suspended
Bay Area Tumor Institute
Oakland, California · Active not recruiting
Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, California · Active not recruiting
Mission Hope Medical Oncology - Santa Maria
Santa Maria, California · Active not recruiting
Epic Care Cyberknife Center
Walnut Creek, California · Active not recruiting
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado · Active not recruiting
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado · Active not recruiting
Showing 40 of 582 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.